Back to News
Market Impact: 0.4
Connect Biopharma Reports Positive Phase 2 Data For Rademikibart In Acute Asthma Exacerbations
Source: Nasdaq
Healthcare & BiotechProduct Launches
Connect Biopharma reported positive preliminary topline data from its global Phase 2 Seabreeze STAT Asthma study of rademikibart as an add-on treatment. The positive clinical readout is a meaningful development for the company’s inflammatory-disease pipeline and could support further advancement of the asthma candidate.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.45
More News
- Backbone of a beast – charting Nvidia's rise to networking titan
- Illumina CEO on Q3 Results and Business Outlook
- UnitedHealth is finally getting its act together. I'm buying into the turnaround
- Swiss Firms Plan Investment Boost in China Drug, Finance Sectors
- Bernstein SocGen raises Eli Lilly stock price target on strong Q3 beat
- Freedom Broker raises Eli Lilly stock price target on GLP-1 demand